Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with Philadelphia chromosome-positive leukemia

Leukemia volume 24, pages 1236–1239 (2010)Cite this article

Subjects

Although allogeneic stem cell transplantation (SCT) is a curative treatment for hematological malignancies, chronic graft-versus-host disease (cGVHD), one of the major complications after SCT, impairs the recipient's quality of life. Therefore, the strategy against cGVHD should be improved.

Recently, it has been reported that the fibrotic change in cGVHD is associated with the activation of transforming-growth-factor-β (TGFβ) and platelet-derived-growth-factor receptor (PDGFR) pathways.1, 2 On the other hand, imatinib, a potent tyrosine kinase inhibitor, is known to inhibit the activation of those pathways,3 and has been investigated for the treatment for steroid-refractory skin cGVHD.4, 5 Although these studies showed that imatinib was effective as salvage treatment for refractory cGVHD, it remains unknown whether the prophylactic imatinib after SCT affects the incidence and severity of cGVHD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Banovic T, MacDonald KP, Morris ES, Rowe V, Kuns R, Don A et al. TGF-beta in allogeneic stem cell transplantation: friend or foe? Blood 2005; 106: 2206–2214.

    Article  CAS  PubMed  Google Scholar 

  2. Svegliati S, Olivieri A, Campelli N, Luchetti M, Poloni A, Trappolini S et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 2007; 110: 237–241.

    Article  CAS  PubMed  Google Scholar 

  3. Alho HS, Maasilta PK, Vainikka T, Salminen US . Platelet-derived growth factor, transforming growth factor-beta, and connective tissue growth factor in a porcine bronchial model of obliterative bronchiolitis. Exp Lung Res 2007; 33: 303–320.

    Article  CAS  PubMed  Google Scholar 

  4. Magro L, Mohty M, Catteau B, Coiteux V, Chevallier P, Terriou L et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood 2009; 114: 719–722.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Olivieri A, Locatelli F, Zecca M, Sanna A, Cimminiello M, Raimondi R et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood 2009; 114: 709–718.

    Article  CAS  PubMed  Google Scholar 

  6. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.

    Article  PubMed  Google Scholar 

  7. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.

    Article  CAS  PubMed  Google Scholar 

  8. Olavarria E, Siddique S, Griffiths MJ, Avery S, Byrne JL, Piper KP et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood 2007; 110: 4614–4617.

    Article  CAS  PubMed  Google Scholar 

  9. Skopouli FN, Li L, Boumba D, Stefanaki S, Hanel K, Moutsopoulos HM et al. Association of mast cells with fibrosis and fatty infiltration in the minor salivary glands of patients with Sjogren's syndrome. Clin Exp Rheumatol 1998; 16: 63–65.

    CAS  PubMed  Google Scholar 

  10. Chinen H, Matsuoka K, Sato T, Kamada N, Okamoto S, Hisamatsu T et al. Lamina propria c-kit+ immune precursors reside in human adult intestine and differentiate into natural killer cells. Gastroenterology 2007; 133: 559–573.

    Article  CAS  PubMed  Google Scholar 

  11. Seggewiss R, Lore K, Greiner E, Magnusson MK, Price DA, Douek DC et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005; 105: 2473–2479.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan

    H Nakasone & Y Kanda

  2. Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan

    H Takasaki, A Maruta & H Kanamori

  3. Department of Hematology, Chiba University Graduate School of Medicine, Chiba, Japan

    C Nakaseko & D Abe

  4. Leukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan

    T Sakura & T Hoshino

  5. Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan

    S Fujisawa

  6. Department of Internal Medicine, Chiba Aoba Municipal Hospital, Chiba, Japan

    A Yokota

  7. Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan

    S Yano

  8. Division of Hematology, Kanto Medical Center, NTT, EC, Tokyo, Japan

    K Usuki

  9. Division of Molecular Therapy, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan

    S Takahashi

  10. Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan

    S Okamoto

Authors
  1. H Nakasone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y Kanda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Takasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Nakaseko
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Sakura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Fujisawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Yokota
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S Yano
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. K Usuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A Maruta
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. D Abe
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. T Hoshino
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. S Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. H Kanamori
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. S Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the Kanto Study Group for Cell Therapy

Corresponding author

Correspondence to Y Kanda.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nakasone, H., Kanda, Y., Takasaki, H. et al. Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with Philadelphia chromosome-positive leukemia. Leukemia 24, 1236–1239 (2010). https://doi.org/10.1038/leu.2010.83

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2010.83

This article is cited by

Search

Advanced search

Quick links